However, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors as single agents have shown modest effects regardless of CDKN2A-altered status in recurrent and metastatic HNSCC (4). Here, CDKN2A is linked to head and neck squamous cell carcinoma.